drugset / Trial / NCT06122831

A Clinical Trial of TQ05105 Tablets Combined With TQB3617 Capsules in the Treatment of Myelofibrosis (MF)

NCT06122831

Phase 1/2 Recruiting 92 enrolled Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
NaSingle-groupOpen-labelTreatment

Summary

This is an open, single-arm, multi-center clinical study designed to evaluate the efficacy and safety of TQ05105 Tablets combined with TQB3617 Capsules in patients with intermediate- and high-risk Myelofibrosis.

Timeline

Start
2023-12-12
Primary completion
2026-12
Completion
2027-04

Drugs

EvaluationDrugModalityDoseRoute
Subject TQ05105 Small molecule Oral
Subject TQB3617 Unknown Oral

Indications